Evercore ISI Starts Arcus Biosciences (RCUS) at Outperform
- S&P 500 closes at record high as Apple, healthcare stocks help shrug off Delta worries
- Tencent (TCEHY) Falls Sharply as State Media Describes Online Games as ‘Spiritual Opium’, Company Vows to Improve
- Oil settles lower in volatile trade on worries about Delta variant
- Clorox (CLX) Falls Sharply as COVID-19 Demand Wanes
- Dollar steadies as markets weigh economic risks, central bank moves
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Evercore ISI analyst Umer Raffat initiates coverage on Arcus Biosciences (NYSE: RCUS) with a Outperform rating.
Shares of Arcus Biosciences closed at $24.38 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Reinstates Delivery Hero SE (DHER:GR) (DLVHF) at Buy
- Ladenburg Thalmann Starts Immutep Limited (IMMP) at Buy
- William Blair Starts Payoneer (PAYO) at Outperform
Create E-mail Alert Related CategoriesNew Coverage
Related EntitiesUmer Raffat
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!